Literature DB >> 17320250

Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins.

Fu-Shi Quan1, Gangadhara Sailaja, Ioanna Skountzou, Chunzi Huang, Andrei Vzorov, Richard W Compans, Sang-Moo Kang.   

Abstract

Extensive glycosylation and variable loops of the HIV envelope protein (Env) are reported to shield some neutralizing epitopes. Here, we investigated the immunogenicity of mutated HIV Envs presented in virus-like particles (VLPs). We immunized mice with simian human immunodeficiency virus (SHIV) VLPs containing mutant HIV Env with reduced glycosylation (3G), variable loop-deleted mutations (dV1V2), or combinations of both types of mutations (3G-dV2-1G), and evaluated immune responses. Immune sera from mice that received VLPs with modified HIV Envs (3G or dV1V2) showed higher neutralizing activities against the homologous HIV 89.6 virus as well as heterologous viruses when compared with wild type SHIV VLP-immunized mice. Lymphocytes from immunized mice produced HIV Env-specific cytokines, with the 3G-dV2-1G mutant producing high levels of cytokines. Interestingly, both dendritic cells and B cells were found to interact with VLPs suggesting that VLPs are effective immunogens. Therefore, this study suggests that VLPs containing modified HIV Env have the potential to be developed as candidate vaccines capable of inducing cellular and humoral immune responses including neutralizing activities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17320250      PMCID: PMC1973151          DOI: 10.1016/j.vaccine.2007.01.107

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  41 in total

Review 1.  A model for neutralization of viruses based on antibody coating of the virion surface.

Authors:  D R Burton; E O Saphire; P W Parren
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

2.  Adeno-associated virus vectors under scrutiny.

Authors:  Kathryn Senior
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

3.  The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Authors:  S W Barnett; S Lu; I Srivastava; S Cherpelis; A Gettie; J Blanchard; S Wang; I Mboudjeka; L Leung; Y Lian; A Fong; C Buckner; A Ly; S Hilt; J Ulmer; C T Wild; J R Mascola; L Stamatatos
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure.

Authors:  Adriaan F G Antonis; Christianne J M Bruschke; Paloma Rueda; Luis Maranga; J Ignacio Casal; Carmen Vela; Luuk A Th Hilgers; Peter B G M Belt; Klaas Weerdmeester; Manuel J T Carrondo; Jan P M Langeveld
Journal:  Vaccine       Date:  2006-04-18       Impact factor: 3.641

5.  Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.

Authors:  D C Montefiori; J T Safrit; S L Lydy; A P Barry; M Bilska; H T Vo; M Klein; J Tartaglia; H L Robinson; B Rovinski
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

Authors:  C D Harro; Y Y Pang; R B Roden; A Hildesheim; Z Wang; M J Reynolds; T C Mast; R Robinson; B R Murphy; R A Karron; J Dillner; J T Schiller; D R Lowy
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

7.  Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques.

Authors:  S E Malenbaum; D Yang; C Cheng-Mayer
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs.

Authors:  Dennis Ellenberger; Linda Wyatt; Bin Li; Suzan Buge; Nattawan Lanier; I Vanesssa Rodriguez; Carlos A Sariol; Melween Martinez; Michael Monsour; Jennifer Vogt; James Smith; Ronald Otten; David Montefiori; Edmundo Kraiselburd; Bernard Moss; Harriet Robinson; Janet McNicholl; Salvatore Butera
Journal:  Virology       Date:  2005-09-15       Impact factor: 3.616

9.  Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains.

Authors:  Anna D LoBue; Lisa Lindesmith; Boyd Yount; Patrick R Harrington; Joseph M Thompson; Robert E Johnston; Christine L Moe; Ralph S Baric
Journal:  Vaccine       Date:  2006-04-18       Impact factor: 3.641

10.  Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.

Authors:  L Buonaguro; L Racioppi; M L Tornesello; C Arra; M L Visciano; B Biryahwaho; S D K Sempala; G Giraldo; F M Buonaguro
Journal:  Antiviral Res       Date:  2002-06       Impact factor: 5.970

View more
  13 in total

1.  Roles of major histocompatibility complex class II in inducing protective immune responses to influenza vaccination.

Authors:  Eunju O; Young-Tae Lee; Eun-Ju Ko; Ki-Hye Kim; Yu-Na Lee; Jae-Min Song; Young-Man Kwon; Min-Chul Kim; Daniel R Perez; Sang-Moo Kang
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

2.  Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsid.

Authors:  Diana V Pastrana; Katherine A Pumphrey; Nicolas Cuburu; Rachel M Schowalter; Christopher B Buck
Journal:  Virology       Date:  2010-07-03       Impact factor: 3.616

3.  Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity.

Authors:  Jaina M Patel; Vincent F Vartabedian; Min-Chul Kim; Sara He; Sang-Moo Kang; Periasamy Selvaraj
Journal:  Biotechnol Bioeng       Date:  2015-04-17       Impact factor: 4.530

4.  Antibody responses against xenotropic murine leukemia virus-related virus envelope in a murine model.

Authors:  Natalia Makarova; Chunxia Zhao; Yuanyuan Zhang; Sushma Bhosle; Suganthi Suppiah; Jeanne M Rhea; Natalia Kozyr; Rebecca S Arnold; Hinh Ly; Ross J Molinaro; Tristram G Parslow; Eric Hunter; Dennis Liotta; John Petros; Jerry L Blackwell
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

5.  Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant.

Authors:  Elena V Vassilieva; Bao-Zhong Wang; Andrei N Vzorov; Li Wang; Ying-Chun Wang; Jadranka Bozja; Rui Xu; Richard W Compans
Journal:  MBio       Date:  2011-02-15       Impact factor: 7.867

6.  Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles.

Authors:  Tea Kirkegaard; Adam Wheatley; Jesper Melchjorsen; Shervin Bahrami; Finn S Pedersen; Robert J Center; Damian F J Purcell; Lars Ostergaard; Mogens Duch; Martin Tolstrup
Journal:  Virol J       Date:  2011-08-01       Impact factor: 4.099

7.  Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells.

Authors:  Juan Pablo Jaworski; Shelly J Krebs; Maria Trovato; Dina N Kovarik; Zachary Brower; William F Sutton; Garrett Waagmeester; Rossella Sartorius; Luciana D'Apice; Antonella Caivano; Nicole A Doria-Rose; Delphine Malherbe; David C Montefiori; Susan Barnett; Piergiuseppe De Berardinis; Nancy L Haigwood
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

8.  Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses.

Authors:  Jaina M Patel; Min-Chul Kim; Vincent F Vartabedian; Yu-Na Lee; Sara He; Jae-Min Song; Hyo-Jick Choi; Satoshi Yamanaka; Nikhil Amaram; Anna Lukacher; Carlo D Montemagno; Richard W Compans; Sang-Moo Kang; Periasamy Selvaraj
Journal:  Nanomedicine       Date:  2015-03-06       Impact factor: 5.307

9.  Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.

Authors:  Gerald V Quinnan; Pengfei Zhang; Ming Dong; Hong Chen; Yan-Ru Feng; Mark Lewis; Christopher C Broder
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

Review 10.  Biomedical applications of glycosylphosphatidylinositol-anchored proteins.

Authors:  Susanne Heider; John A Dangerfield; Christoph Metzner
Journal:  J Lipid Res       Date:  2016-08-19       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.